Medtronic Completes Oversubscribed MiniMed Spin-Off Exchange

  • Medtronic's exchange offer for MiniMed shares was oversubscribed, with 298 million Medtronic shares tendered.
  • Medtronic will exchange 55 million of its shares for 252.8 million MiniMed shares, representing an 18.3% proration.
  • The exchange offer expired on October 9, 2026, with final proration details to be announced on October 14, 2026.
  • Medtronic will retain no MiniMed shares post-exchange, completing the spin-off.

Medtronic's completion of the MiniMed spin-off marks a strategic shift to streamline its portfolio, focusing on core healthcare technology segments. The oversubscription indicates strong investor interest in MiniMed's diabetes management business, which could become a key player in the medical devices sector. The transaction's success will hinge on MiniMed's ability to compete independently and Medtronic's capacity to integrate the changes without operational disruptions.

Spin-Off Execution
Whether MiniMed can operate successfully as an independent company post-separation.
Market Reaction
How investors will value MiniMed as a standalone entity and the impact on Medtronic's stock.
Regulatory Compliance
The pace at which Medtronic completes the transaction on a tax-free basis for shareholders.